Neuropeptides and anxiety: Focus on cholecystokinin

Clinical Chemistry

Volumn 40, Issue 2, 1994, Pages 315-318

  Lydiard, R Bruce ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; BENZODIAZEPINE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; LORGLUMIDE; NEUROPEPTIDE; NEUROTRANSMITTER; TETRAGASTRIN;

ANXIETY; BULIMIA; CEREBROSPINAL FLUID LEVEL; CONFERENCE PAPER; DRUG EFFECT; HUMAN; NONHUMAN; OBSESSION; PANIC; STRESS;

ANIMALIA;

EID: 0028347050     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/40.2.315     Document Type: Conference Paper

References (34)

1. Vancerhaeghen J-J, Signeau JC, Gepts W. New peptide in the vertebrate CNS interacting with antigastrin antibodies. Nature 1975;257:604-5.
2. Moran TH, Robinson PH, Goldrich MS, McHugh PR. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986;362:175-9.
3. Hill DR, Singh L, Boden P, Pinnick R, Woodruff GN, Hughes J. In: Cooper ST, Dourish CD, Iversen SD, eds. Multiple cholecystokinin in the CNS. Oxford: Oxford University Press, 1992:57-76.
4. Della-Ferra MA, Bailey CA. Cholecystokinin octapeptide: continuous picomole injections into the cerebral ventricles of sheep suppress feeding. Science 1979;206:471-3.
5. Bradwejn J, de Montigney C. Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature 1984;312:363-4.
6. Bradwejn J, de Montigny C. Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat. Eur J Pharmacol 1985;112:415-8.
7. Fekete M, Lengyel A, Hegedus B, Penke B, Zarandy M, Toth GK, Telegdy G. Further analysis of the effects of cholecystokinin octapeptide on avoidance in rats. Eur J Pharmacol 1984;98:79-91.
8. Harro J, Vasar E, Bradwejn J. Cholecystokinin in animal and human research on anxiety. Trends Pharm Sci 1993;14:244-9.
9. Ervin F, Palmour R, Bradwejn J. A new primate model for panic disorder [Abstract]. New Orleans: New Research Program and Abstracts, 144th meeting Am Psychiatric Assoc, May 1991: NR216.
10. Palmour R, Ervin F, Bradwejn J, Howbert J. The anxiogenic and cardiovascular effects of CCK-4 are blocked by the CCK-B receptor antagonist LY262 691 [Abstract 637.1]. Soc Neurosci 1991;17:1602.
11. Hendry SHC, Jones EG, Defilipe J, Schmechell D, Brandon D, Emson PC. Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. Proc Natl Acad Sci USA 1984;81:6526-30.
12. Harro J, Vasar E. Long-term benzodiazepine treatment produces changes in cholecystokinin receptor binding in rat brain. Eur J Pharmacol 1990;180:77-83.
13. Paudice P, Ratieri M. Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens. Br J Pharmacol 1991;103:1790-4.
14. Harro J, Jossan SS, Oreland L. Changes in cholecystokinin receptor binding in rat brain after selective damage of locus ceruleus projections by DSP-4 treatment. Naunyn-Schmiedeberg Arch Pharmacol 1992;346:425-31.
15. Phillipp E, Wilckens T, Friess E, Platte P, Pirke KM. Cholecystokinin, gastrin, and stress hormone responses in marathon runners. Peptides 1992;13:125-8.
16. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy subjects. Arch Gen Psychiatry 1989;46:511-7.
17. Bradwejn J, Koszycki D, Couteoux du Tertre A, Bourin M, Palmour R, Ervin F. The cholecystokinin hypothesis of panic and anxiety disorders [Review]. J Psychopharmacol 1992;6:345-51.
18. Bradwejn J, Koszycki D, Metterissian G. Cholecystokinin-tetrapeptide induced panic attacks in patients with panic disorder. Can J Psychiatry 1990;35:83-5.
19. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 1991;48:603-10.
20. 2-induced panic attacks with cholecystokinin-induced attacks in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:237-9.
21. Bradwejn J, Koszycki D, Dutertre AC, Van Megan H, den Boer J, Westenberg H, et al. L-365,260, a CCK-B antagonist, blocks CCK-4 in panic disorder [Abstract]. Charleston, SC: Anxiety Disorders Assoc of America annual meeting, March 1993.
22. Abelson JL, Nesse RM. CCK-4 and panic [Letter]. Arch Gen Psychiatry 1990;47:395.
23. Abelson JL, Nesse RM. Neuroendocrine, cardiovascular, and behavioral responses to a cholecystokinin receptor agonist in patients with panic disorder [Abstract]. Charleston, SC: Anxiety Disorders Assoc of America annual meeting, March 1993.
24. Gorman J, Liebowitz MR, Fyer AJ, Stein J. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry 1989;146:148-61.
25. Branchereau P, Bohme GA, Champagnat J, Morin-Surun M-P, Durieux C, Blanchard JC, et al. Cholecystokinin A and cholecystokinin B receptors in neurons of the brainstem solitary complex of the rat: pharmacologic identification. J Pharm Exp Ther 1992;260:1433-40.
26. Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Beinfeld MC. CSF cholecystokinin concentrations in patients with panic disorder and normal comparison subjects. Am J Psychiatry 1992;149:691-3.
27. Denavit-Soubie M, Hurle MA, Morin-Suryn MP, Soutz AS, Champagnat J. The effect of cholecystokinin-8 on the nucleus tractus solitarius. Ann NY Acad Sci 1985;48:375-84.
28. Lydiard RB, Zealberg J, Fossey MD, Beinfeld MC, Ballenger JC. CSF cholecystokinin octapeptide in OCD and normals [Abstract]. San Juan, PR: American College of Neuropsychopharmacology, December 1992.
29. Lydiard RB, Brewerton TD, Fossey MD, Laraia MT, Stuart G, Beinfeld MC, Ballenger JC. CSF cholecystokinin octapeptide in patients with bulimia nervosa and normal comparison subjects. Am J Psychiatry 1993;150:1099-101.
30. Geraciotti TD, Liddle RA Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med 1988;319:683-8.
31. Woodruff GN, Hughes J. Cholecystokinin antagonists. Ann Rev Pharmacol Toxicol 1991;31:469-501.
32. Hughes J, Boden P, Costall B, Domeney A, Kelley E. Development of a class of selective cholecystokinin receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990; 87:6728-32.
33. Helton D, Rasmussen K, Berger J, Scearce E. The selective cholecystokinin-B (CCK-B) antagonist LY288513 attenuates increases in sensorimotor reactivity from withdrawal from chronic diazepam [Abstract]. Chatham, MA: CCK '93, May 1993.
34. Singh L, Hughes J, Field M, Woodruff GN. The effects of the CCK-B receptor antagonist CI-988 on withdrawal from chronic alcohol treatment [Abstract]. Keystone, CO: Committee on Problems of Drug Dependence, June 1992.